PE20080112A1 - Anticuerpo humanizado especifico para tslp (linfopoyetina estromal timica) y composiciones farmaceuticas - Google Patents

Anticuerpo humanizado especifico para tslp (linfopoyetina estromal timica) y composiciones farmaceuticas

Info

Publication number
PE20080112A1
PE20080112A1 PE2007000198A PE2007000198A PE20080112A1 PE 20080112 A1 PE20080112 A1 PE 20080112A1 PE 2007000198 A PE2007000198 A PE 2007000198A PE 2007000198 A PE2007000198 A PE 2007000198A PE 20080112 A1 PE20080112 A1 PE 20080112A1
Authority
PE
Peru
Prior art keywords
seq
tslp
region selected
humanized antibody
stromal
Prior art date
Application number
PE2007000198A
Other languages
English (en)
Inventor
Michael Bardroff
Matthew Edwards
Mehmet Tur
Olaf Ratsch
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080112A1 publication Critical patent/PE20080112A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANIZADO AISLADO O UN FRAGMENTO FUNCIONAL QUE COMPRENDE UNA REGION DE ENLACE CON ANTIGENO QUE ES ESPECIFICA PARA TSLP (LIFOPOYETINA ESTROMAL TIMICA HUMANA) CON UNA KD DE 1x10-9 M O MENOS. DICHO ANTICUERPO COMPRENDE: A) UNA REGION L-CDR1 SELECCIONADA DE SEQ ID N0:38, UNA REGION L-CDR2 SELECCIONADA DE SEQ ID N0:47, UNA REGION L-CDR3 SELECCIONADA DE SEQ ID N0:60; B) UNA REGION H-CDR1 SELECCIONADA DE SEQ ID N0:3, UNA REGION H-CDR2 SELECCIONADA DE SEQ ID: 15, SEQ ID:17, SEQ ID:18, SEQ ID:19, SEQ ID:20 Y UNA REGION H-CDR3 SELECCIONADA DE SEQ ID:28 Y VARIANTES CONSERVADORAS DE LAS MISMAS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA CON EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES TALES COMO EL ASMA, DERMATITIS ATOPICA, RINITIS ALERGICA, FIBROSIS, ENFERMEDAD INFLAMATORIA DEL INTESTINO Y EL LINFOMA DE HODKIN
PE2007000198A 2006-02-23 2007-02-22 Anticuerpo humanizado especifico para tslp (linfopoyetina estromal timica) y composiciones farmaceuticas PE20080112A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0603683.4A GB0603683D0 (en) 2006-02-23 2006-02-23 Organic compounds

Publications (1)

Publication Number Publication Date
PE20080112A1 true PE20080112A1 (es) 2008-03-13

Family

ID=36178659

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000198A PE20080112A1 (es) 2006-02-23 2007-02-22 Anticuerpo humanizado especifico para tslp (linfopoyetina estromal timica) y composiciones farmaceuticas

Country Status (24)

Country Link
US (2) US8420787B2 (es)
EP (2) EP2341076A3 (es)
JP (1) JP2009527235A (es)
KR (1) KR20080099330A (es)
CN (1) CN101389657A (es)
AR (1) AR059867A1 (es)
AU (1) AU2007218165A1 (es)
BR (1) BRPI0708145A2 (es)
CA (1) CA2638851A1 (es)
CL (1) CL2007000478A1 (es)
CR (1) CR10184A (es)
EC (1) ECSP088690A (es)
ES (1) ES2404058T3 (es)
GB (1) GB0603683D0 (es)
IL (1) IL193229A0 (es)
MA (1) MA30274B1 (es)
MX (1) MX2008010807A (es)
NO (1) NO20083911L (es)
PE (1) PE20080112A1 (es)
RU (1) RU2008137531A (es)
TN (1) TNSN08333A1 (es)
TW (1) TW200813089A (es)
WO (1) WO2007096149A1 (es)
ZA (1) ZA200806490B (es)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6702949B2 (en) 1997-10-24 2004-03-09 Microdiffusion, Inc. Diffuser/emulsifier for aquaculture applications
JP4454859B2 (ja) * 1998-11-13 2010-04-21 イミュネックス・コーポレーション ヒトｔｓｌｐｄｎａおよびポリペプチド
US7288633B2 (en) * 2001-07-23 2007-10-30 Immunex Corporation Modified human thymic stromal lymphopoietin
EP2860192B1 (en) * 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
PL2500360T3 (pl) 2005-10-31 2016-01-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
EP3170401B1 (en) 2006-10-25 2019-06-05 Revalesio Corporation Ionic aqueous fluid composition containing oxygen microbubbles
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
WO2008052145A2 (en) 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
CN101605814B (zh) 2006-12-14 2014-02-19 默沙东公司 经工程改造的抗tslp抗体
EP3424529A1 (en) 2007-07-02 2019-01-09 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
WO2009023184A2 (en) * 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
MX2010004563A (es) * 2007-10-25 2010-07-28 Revalesio Corp Composiciones y métodos para modular la transducción de la señal intracelular mediada por la membrana celular.
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
BRPI0911757A2 (pt) 2008-05-01 2013-09-17 Revalesio Corp composiÇÕes e mÉtodos para tratar distérbios digestivos.
JP5792621B2 (ja) 2008-09-26 2015-10-14 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US8637019B2 (en) * 2009-11-04 2014-01-28 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
MX347515B (es) 2010-04-01 2017-04-28 Oncomed Pharmaceuticals Inc * Agentes que se unen al receptor encrespado y usos de los mismos.
MX2012012971A (es) 2010-05-07 2013-02-07 Revalesio Corp Composiciones y metodos para mejorar el rendimiento fisiologico y el tiempo de recuperacion.
BR112013003110A2 (pt) 2010-08-12 2016-06-28 Revalesio Corp composições e métodos para tratamento de taupatia
US8802097B2 (en) 2011-07-15 2014-08-12 Oncomed Pharmaceuticals, Inc. Anti-RSPO1 antibodies
JP2015502917A (ja) * 2011-10-28 2015-01-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｔｓｌｐ処置のバイオマーカーとしてのｉｌ−１９
US9732151B2 (en) 2011-11-03 2017-08-15 Merck Sharp & Dohme Corp. Biomarkers for TSLP treatment
MX2015000565A (es) 2012-07-13 2015-04-10 Oncomed Pharm Inc Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos.
CN104768579A (zh) 2012-10-23 2015-07-08 昂科梅德制药有限公司 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CA2932424C (en) * 2013-12-06 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
AU2015256082C1 (en) 2014-05-07 2020-09-10 Amgen Inc. Autoinjector with shock reducing elements
JP6671298B2 (ja) 2014-05-16 2020-03-25 アムジェン インコーポレイテッド Ｔｈ１及びｔｈ２細胞集団を検出するためのアッセイ
CN112237662B (zh) 2014-06-03 2022-10-21 安姆根有限公司 药物递送系统和使用方法
US10064937B2 (en) 2014-09-16 2018-09-04 Oncomed Pharmaceuticals, Inc. Treatment of dermal fibrosis
AU2015332557B2 (en) 2014-10-14 2020-05-14 Amgen Inc. Drug injection device with visual and audio indicators
CN107206070B (zh) 2014-10-23 2022-01-18 美国安进公司 降低药物制剂的粘度
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
TW201643179A (zh) * 2015-03-11 2016-12-16 葛蘭素史克智慧財產發展有限公司 Ｔｓｌｐ結合蛋白
KR101843248B1 (ko) * 2015-03-17 2018-03-29 고려대학교 세종산학협력단 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017042701A1 (en) * 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
HUE053914T2 (hu) * 2015-09-09 2021-07-28 Novartis Ag Csecsemõmirigy-stróma eredetû limfopoietinhez (TSLP-hez) kötõdõ ellenanyagok és az ellenanyagok alkalmazására szolgáló eljárások
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
GB201615588D0 (en) * 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
EP3429663B1 (en) 2016-03-15 2020-07-15 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
EP3443984A4 (en) 2016-04-15 2019-04-10 Pontificia Universidad Católica De Chile PHARMACEUTICAL COMPOSITION FOR REDUCING THE SYMPTOMS AND THE SERIOUS DEGREE OF RESPIRATORY INFECTION BY human metapneumovirus (hMPV) WITH AT LEAST ONE FUNCTION OF TSLP- AND / OR TSLPR- AND / OR OX40L- AND / OR CD177-MOLECULE neutralizing agent AND PHARMACEUTICAL ACCEPTABLE ALTERNATIVE FUEL AND USE THEREOF
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
CN107955071B (zh) * 2016-10-18 2021-03-26 上海赛远生物科技有限公司 人源抗人cd47抗体及其编码基因与应用
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
EP3592403A1 (en) 2017-03-06 2020-01-15 Amgen Inc. Drug delivery device with activation prevention feature
IL268478B2 (en) 2017-03-07 2023-10-01 Amgen Inc Inserting a needle using super pressure
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
CN106943593A (zh) * 2017-03-24 2017-07-14 浙江中医药大学 抗tslp抗体在制备防治慢性瘙痒药物中的应用
EP4241807A3 (en) 2017-03-28 2023-10-11 Amgen Inc. Plunger rod and syringe assembly system and method
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
US11541183B2 (en) 2017-06-22 2023-01-03 Amgen Inc. Device activation impact/shock reduction
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
ES2972207T3 (es) 2017-07-14 2024-06-11 Amgen Inc Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
MA49626A (fr) 2017-07-21 2020-05-27 Amgen Inc Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
KR20200040803A (ko) * 2017-08-16 2020-04-20 메디뮨 엘엘씨 아토피 피부염의 치료 및 치료 선택을 위한 조성물 및 방법
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
IL272636B1 (en) 2017-10-06 2024-06-01 Amgen Inc Drug delivery device with combination assembly and related assembly method
WO2019074579A1 (en) 2017-10-09 2019-04-18 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
SG11202002966QA (en) 2017-11-10 2020-05-28 Amgen Inc Plungers for drug delivery devices
IL273638B1 (en) 2017-11-16 2024-06-01 Amgen Inc Door lock mechanism for drug delivery device
TWI710577B (zh) * 2018-04-18 2020-11-21 偉喬生醫股份有限公司 單離抗硫酸吲哚酚之單株抗體及/或其抗原結合片段之組成物暨其使用
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US12042645B2 (en) 2018-07-24 2024-07-23 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (en) 2018-10-02 2021-08-11 Amgen Inc. Injection systems for drug delivery with internal force transmission
EP3860686A1 (en) 2018-10-05 2021-08-11 Amgen Inc. Drug delivery device having dose indicator
CA3109988A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
MA53912A (fr) 2018-10-15 2022-01-19 Amgen Inc Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
CA3113076A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
CN109678957B (zh) * 2018-12-06 2021-04-06 浙江工业大学 一种抗人tslp单克隆抗体及其制备与应用
MX2021012557A (es) 2019-04-24 2021-11-12 Amgen Inc Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
WO2020244544A1 (zh) * 2019-06-04 2020-12-10 江苏恒瑞医药股份有限公司 能结合胸腺基质淋巴细胞生成素的抗体及其应用
US20220251186A1 (en) * 2019-07-11 2022-08-11 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
EP4025602A4 (en) * 2019-09-04 2023-12-13 Biosion, Inc. TSLP-BINDING ANTIBODIES AND THEIR USES
CN114887053A (zh) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
JP2023505408A (ja) * 2019-12-13 2023-02-09 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ｔｓｌｐ抗体及びその使用
CN111883211B (zh) * 2020-08-07 2021-04-23 张哲� 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法
CN114437212B (zh) * 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
WO2022100664A1 (zh) * 2020-11-12 2022-05-19 上海济煜医药科技有限公司 一种tslp抗原结合蛋白及其应用
EP4288454A1 (en) * 2021-02-04 2023-12-13 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing thymic stromal lymphopoietin and uses thereof
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
MX2023009971A (es) * 2021-03-03 2023-09-05 Chia Tai Tianqing Pharmaceutical Group Co Ltd Composicion farmaceutica que contiene anticuerpo anti-tslp.
US20240208680A1 (en) 2021-05-21 2024-06-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
CN115433275A (zh) * 2021-06-02 2022-12-06 启愈生物技术(上海)有限公司 抗胸腺基质淋巴细胞生成素（tslp）抗体及其用途
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
CN113683694B (zh) * 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209603B (zh) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
EP2314696A1 (en) 1998-09-21 2011-04-27 Schering Corporation Therapeutic uses of human Interleukin-B50 antagonist.
JP4454859B2 (ja) 1998-11-13 2010-04-21 イミュネックス・コーポレーション ヒトｔｓｌｐｄｎａおよびポリペプチド
US6890734B2 (en) 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
NZ533987A (en) 2002-02-01 2007-04-27 Schering Corp Uses of mammalian cytokine; agonists and antagonists for modulating antigen presenting cell priming of T cells
US20060171943A1 (en) 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
CN101605814B (zh) 2006-12-14 2014-02-19 默沙东公司 经工程改造的抗tslp抗体
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin

Also Published As

Publication number Publication date
GB0603683D0 (en) 2006-04-05
CN101389657A (zh) 2009-03-18
TW200813089A (en) 2008-03-16
ES2404058T3 (es) 2013-05-23
WO2007096149A1 (en) 2007-08-30
US20090186022A1 (en) 2009-07-23
RU2008137531A (ru) 2010-03-27
CL2007000478A1 (es) 2008-03-14
EP1991583B1 (en) 2012-12-19
ZA200806490B (en) 2009-06-24
TNSN08333A1 (en) 2009-12-29
US20130323237A1 (en) 2013-12-05
NO20083911L (no) 2008-11-05
MA30274B1 (fr) 2009-03-02
KR20080099330A (ko) 2008-11-12
AU2007218165A1 (en) 2007-08-30
BRPI0708145A2 (pt) 2011-05-17
AR059867A1 (es) 2008-05-07
ECSP088690A (es) 2008-09-29
US8420787B2 (en) 2013-04-16
JP2009527235A (ja) 2009-07-30
EP1991583A1 (en) 2008-11-19
IL193229A0 (en) 2009-02-11
EP2341076A2 (en) 2011-07-06
CR10184A (es) 2008-12-03
EP2341076A3 (en) 2011-08-24
CA2638851A1 (en) 2007-08-30
MX2008010807A (es) 2008-09-01

Similar Documents

Publication Publication Date Title
PE20080112A1 (es) Anticuerpo humanizado especifico para tslp (linfopoyetina estromal timica) y composiciones farmaceuticas
PE20080036A1 (es) Anticuerpos humanos para la interleucina-13 (il13)
HRP20192280T1 (hr) Anti-ceacam6 protutijela i njihova uporaba
SA519410311B1 (ar) أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
WO2006110214A3 (en) Antibodies against mammalian metapneumovirus
BR112014021251A2 (pt) anticorpos humanos para toxinas de clostridium difficile
AR108663A1 (es) ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
MX2009005743A (es) Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab.
MY157948A (en) Humanized anti-factor d antibodies
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201000809A1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА
NZ603883A (en) Method for preparing antibodies having improved properties
PH12017501075A1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
AR085198A1 (es) Composicion farmaceutica
PE20090321A1 (es) Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CL2012002536A1 (es) Composición farmacéutica que comprende un anticuerpo anti-factor de crecimiento nervioso (ngf) o un fragmento de unión al antígeno de éste, un amortiguador histidina 5 a 60mm, polisorbato 80 0,01% a 0,1%, y un ph entre 5,0 y 6,0; composición liofilizada; dispositivo; artículo de manufactura; y su uso en enfermedades mediadas por ngf, tales como trastornos del dolor.
GT201200318A (es) Anticuerpos hacia gdf8 humano
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
TR201907261T4 (tr) DKK-1 antikorları.
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
PE20141149A1 (es) Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
WO2020076969A3 (en) Anti-lap antibody variants and uses thereof
NI201200144A (es) Anticuerpos humanizados de il - 25

Legal Events

Date Code Title Description
FC Refusal